CoChat

An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions

Open access
Schifano, Fabrizio, Chiappini, Stefania, Corkery, John M, Guirguis, Amira · 2019 · International Journal of Neuropsychopharmacology

The DOI matches its Crossref record; 47 of the 51 references it cites were found in a registry or an index; 2 of the 33 sources its claims cite were checked for support.

Abstract

BACKGROUND: Although originally marketed as safe alternatives to the habit-forming benzodiazepines, growing numbers of zaleplon, zolpidem, and zopiclone ("Z-drugs") clinical concerns relating to their potential of abuse, dependence, and withdrawal have been reported over time. We aimed here at assessing these issues analyzing datasets of adverse drug reactions provided by the European Medicines Agency through the EudraVigilance system. METHODS: Analyzing the adverse drug reactions databases of each Z-drug, descriptive analyses have been performed on cases and proportional reporting ratios (PRRs) computed. RESULTS: An overall number of 33 240 (e.g., 23 420 zolpidem; 9283 zopiclone; and 537 zaleplon) misuse-, abuse-, dependence-, and withdrawal-related adverse drug reactions, corresponding to some 6246 unique patients given Z-drugs, were here identified. Cases were studied and described, including demographic characteristics and clinical data such as concomitant drugs, doses, routes of administration, and outcomes of the reactions (being fatalities recorded). Considering PRR values and in comparison with zopiclone, zolpidem was more frequently involved in both misuse/abuse and withdrawal issues. Zolpidem and zopiclone presented with the same dependence risk, but zopiclone was most involved in overdose adverse drug reactions. Compared with zaleplon, zopiclone presented higher dependence and overdose-related issues but slightly lower misuse/abuse and withdrawal PRR values. CONCLUSION: Current data may only represent a gross underestimate of the real prevalence of Z-drug misuse. Caution should be exercised when prescribing those molecules, especially for patients with psychiatric illnesses and/or history of drug abuse. We recommend the need to invest in proactive pharmacovigilance activities to better and promptly detect, understand, and prevent any possible misuse potential of prescribed medications.

Overview

CoChat Summary

## TL;DR

This pharmacovigilance study mined the EMA EudraVigilance database for Z-drug misuse, abuse, dependence, and withdrawal reports and found substantial reporting across zolpidem, zopiclone, and zaleplon. The authors conclude these data likely underestimate real-world misuse and support caution, especially in patients with psychiatric illness or a history of drug abuse.

## Key findings

  • The database search identified 33,240 misuse/abuse/dependence/withdrawal-related adverse drug reactions (ADRs), corresponding to 6,246 unique patients using Z-drugs.
  • By drug, the identified ADRs were 23,420 zolpidem, 9,283 zopiclone, and 537 zaleplon.
  • Compared with zopiclone, zolpidem was reported more often for misuse/abuse and withdrawal; zolpidem and zopiclone had the same dependence risk; and zopiclone was more involved in overdose ADRs.
  • Reported fatal outcomes were highest for zolpidem (20.3%), compared with zopiclone (9.33%) and zaleplon (1.1%). In the text, zaleplon is described as the comparatively least misused / lower-risk Z-drug.

## Methods

  • The study used a descriptive pharmacovigilance analysis of EMA EudraVigilance individual case safety reports for Z-drug-related misuse, abuse, dependence, and withdrawal.
  • The author requested all relevant reports using MedDRA preferred terms and Standardised MedDRA Queries related to drug abuse/dependence/withdrawal; the analysis covered 2003 to 2017 for zaleplon, 206,315 zolpidem ADRs, and 65,140 zopiclone ADRs as the drug-specific source pools reported in the text.
  • Analyses included descriptive summaries and proportional reporting ratios (PRRs) comparing drugs on misuse/abuse, dependence, withdrawal, and overdose reporting.

## Limitations

  • The paper states the data likely underestimate the real prevalence of Z-drug misuse because reporting is voluntary and depends on clinician awareness, drug availability, and extent of use.
  • The authors note that reports had missing data (for example, dosages ingested and background diagnosis), and that duplicate reports were possible, although they tried to mitigate this with unique case codes.
  • Evident from the text: the study uses suspected ADR reports, so the reports do not prove causality between a Z-drug and the event, and the database lacks a reliable denominator for actual exposure/availability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyz007

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

2 Valid · 0 Not valid · 16 Not checked · 34 Own results and interpretations

28 more claims

Create a free account to see all 52 claims and to verify the 31 references still open.

See all claims — free account
  • It may state two separate claims as one. 12
  • Probably not a substantial claim. 9

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 47 references

Research works printed but not linked: 3

  1. Casula, 2013, UK deaths associated with ‘Z’ drugs (Zopiclone, Zolpidem & Zaleplon) in Z-drugs: a review of the evidence of misuse and harm, 19
  2. Desousa, 2009, Zaleplon abuse, JPPS, 5, 31
  3. Medical Dictionary for Regulatory Activities (MedDRA), 2018, Introductory guide for Standardised MedDRA Queries (SMQs) Version 21.0

Cited by

See all 194

Metadata

Authors
Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A.
Affiliations
University of Hertfordshire (GB)
Corresponding author
Chiappini, Stefania
Venue
International Journal of Neuropsychopharmacology
Published
2019-02-05
Volume
22
Issue
4
Pages
270-277
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2914189181
Cited by
194
References
51
Citations by year
2026: 26 · 2025: 23 · 2024: 29 · 2023: 35 · 2022: 24 · 2021: 31 · 2020: 19 · 2019: 6
FWCI
14.73
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion, cc-by-nc)
  • University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion)
Funders
EMA
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Keywords
Z-drugs, zaleplon, zolpidem, zopiclone, drug abuse, drug addiction, withdrawal, misuse, drug overdose, adverse drug reactions, pharmacovigilance, benzodiazepine alternatives, EudraVigilance, proportional reporting ratio
MeSH terms
Drug Misuse, Zolpidem, Acetamides, Adolescent, Adult, Europe, Female, Humans, Hypnotics and Sedatives, Male, Middle Aged, Piperazines, Pyrimidines, Databases, Factual, Substance-Related Disorders, Azabicyclo Compounds, Young Adult, Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. https://app.cochat.ai/papers/10.1093/ijnp/pyz007
The paper
Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019). An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyz007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.